Harrow, Inc. Stock Redeemed or Called During Period, Value
Harrow, Inc. (HROW) reported Stock Redeemed or Called During Period, Value of $11.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-23.
Discontinued › Shareholders' Equity
us-gaap:StockRedeemedOrCalledDuringPeriodValue · last filed 2023-03-23
- Harrow, Inc. stock redeemed or called during period, value for the quarter ending 2021-12-31 was $0.00.
- Harrow, Inc. stock redeemed or called during period, value for the quarter ending 2021-09-30 was $0.00.
- Harrow, Inc. stock redeemed or called during period, value for the quarter ending 2021-06-30 was $11.00M.
- Harrow, Inc. stock redeemed or called during period, value for fiscal 2021 was $11.00M.
| Period end | Stock Redeemed or Called During Period, Value 3 month | Stock Redeemed or Called During Period, Value 3 month as first filed | Stock Redeemed or Called During Period, Value 6 month | Stock Redeemed or Called During Period, Value 6 month as first filed | Stock Redeemed or Called During Period, Value 9 month | Stock Redeemed or Called During Period, Value 9 month as first filed | Stock Redeemed or Called During Period, Value 12 month |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $11.00M derived: sum of 3 quarters · filed 2023-03-23 | $11.00M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $11.00M derived: sum of 2 quarters · filed 2022-11-14 | $11.00M 10-Q · filed 2022-11-14 | -$11.00M 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $11.00M 10-Q · filed 2022-08-09 | -$11.00M 10-Q · filed 2021-08-10 | $11.00M 10-Q · filed 2022-08-09 | -$11.00M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |